Quality of life in schizophrenia: relationship to sociodemographic factors, symptomatology and tardive dyskinesia, Acta Psychiatr Scand, vol.94, issue.2, pp.118-124, 1996. ,
Rate and risk factors of depressive symptoms in Chinese patients presenting with first-episode non-affective psychosis in Hong Kong, Schizophr Res, vol.168, issue.1-2, pp.99-105, 2015. ,
Not all drug-induced parkinsonism are the same: the effect of drug class on motor phenotype, Neurol Sci Off J Ital Neurol Soc Ital Soc Clin Neurophysiol, 2016. ,
World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the longterm treatment of schizophrenia and management of antipsychotic-induced side effects, World J Biol Psychiatry Off J World Fed Soc Biol Psychiatry, vol.14, issue.1, pp.2-44, 2013. ,
Pharmacologic treatment of schizophrenia, Biol Psychiatry, vol.46, issue.10, pp.1396-1408, 1999. ,
Incidence of extrapyramidal symptoms and tardive dyskinesia in schizophrenia: thirty-six-month results from the European schizophrenia outpatient health outcomes study, J Clin Psychopharmacol, vol.30, issue.5, pp.531-540, 2010. ,
Spontaneous movement disorders in antipsychotic-naive patients with firstepisode psychoses: a systematic review, Psychol Med, vol.39, issue.7, pp.1065-1076, 2009. ,
Incidence and distribution of parkinsonism in Olmsted County, Neurology, vol.52, issue.6, pp.1214-1220, 1976. ,
Imaging of the dopamine transporter predicts pattern of disease progression and response to levodopa in patients with schizophrenia and parkinsonism: a 2-year follow-up multicenter study, Schizophr Res, vol.152, issue.2-3, pp.344-349, 2014. ,
FP-CIT single photon emission computed tomography findings in drug-induced Parkinsonism, Schizophr Res, vol.123, issue.1, pp.40-45, 2012. ,
Extrapyramidal symptoms during treatment of first schizophrenia episode: results from EUFEST, Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol, vol.24, issue.9, pp.1500-1505, 2014. ,
Severity of Tardive Dyskinesia and Negative Symptoms are Associated with Poor Quality of Life in Schizophrenia Patients (PDF Download Available), Int Med J, vol.20, pp.677-680, 2013. ,
Tardive dyskinesia (syndrome): Current concept and modern approaches to its management, Psychiatry Clin Neurosci, vol.69, issue.6, pp.321-334, 2015. ,
Spontaneous involuntary disorders of movement: their prevalence, severity, and distribution in chronic schizophrenics with and without treatment with neuroleptics, Arch Gen Psychiatry, vol.39, issue.4, pp.452-461, 1982. ,
Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial, Schizophr Res, vol.80, issue.1, pp.33-43, 2005. ,
Second-generation versus firstgeneration antipsychotic drugs for schizophrenia: a meta-analysis, Lancet Lond Engl, vol.373, issue.9657, p.61764, 2009. ,
Second-generation antipsychotic drugs and extrapyramidal side effects: a systematic review and meta-analysis of head-to-head comparisons, Schizophr Bull, vol.38, issue.1, pp.167-177, 2012. ,
Tardive dyskinesia in relation to estimated dopamine D2 receptor occupancy in patients with schizophrenia: analysis of the CATIE data, Schizophr Res, vol.153, issue.1-3, pp.184-188, 2014. ,
Akathisia: prevalence and risk factors in a communitydwelling sample of patients with schizophrenia. Results from the FACE-SZ dataset, Schizophr Res, vol.169, issue.1-3, pp.255-261, 2015. ,
URL : https://hal.archives-ouvertes.fr/hal-01896595
Tardive Dyskinesia Prevalence in the Period of Second-Generation Antipsychotic Use: A Meta-Analysis, J Clin Psychiatry, 2017. ,
A National network of schizophrenia expert centres: An innovative tool to bridge the research-practice gap, Eur Psychiatry J Assoc Eur Psychiatr, vol.30, issue.6, pp.728-735, 2015. ,
The positive and negative syndrome scale (PANSS) for schizophrenia, Schizophr Bull, vol.13, issue.2, pp.261-276, 1987. ,
Searching for a consensus five-factor model of the Positive and Negative Syndrome Scale for schizophrenia, Schizophr Res, vol.137, issue.1, pp.246-250, 2012. ,
Study of the concurrent validity of the Calgary Depression Scale for Schizophrenics (CDSS), J Affect Disord, vol.58, issue.2, pp.107-115, 2000. ,
The Brief Adherence Rating Scale (BARS) validated against electronic monitoring in assessing the antipsychotic medication adherence of outpatients with schizophrenia and schizoaffective disorder, Schizophr Res, vol.100, issue.1-3, pp.60-69, 2008. ,
Determination of Adherence Profiles in Schizophrenia Using Self-Reported Adherence: Results From the FACE-SZ Dataset, J Clin Psychiatry, vol.77, issue.9, pp.1130-1136, 2016. ,
Dose Equivalents for Second-Generation Antipsychotics: The Minimum Effective Dose Method, Schizophr Bull, vol.40, issue.2, pp.314-326, 2014. ,
Systematic evaluation of rating scales for drug-induced parkinsonism and recommendations for future research, J Clin Psychopharmacol, vol.30, issue.1, pp.57-63, 2010. ,
Validity of Simpson-Angus Scale (SAS) in a naturalistic schizophrenia population, BMC Neurol, vol.5, issue.1, p.5, 2005. ,
Evaluation of the routine clinical use of the Brief Psychiatric Rating Scale (BPRS) and the Abnormal Involuntary Movement Scale (AIMS). -Semantic Scholar, J Psychiatr Pract, vol.17, pp.300-303, 2011. ,
Treatment adherence in schizophrenia: a patient-level meta-analysis of combined CATIE and EUFEST studies, Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol, vol.25, issue.8, pp.1158-1166, 2015. ,
Neuroleptic intolerance, Schizophr Bull, vol.23, issue.4, pp.567-582, 1997. ,
Prevalence of neuroleptic-induced movement disorders in chronic schizophrenia inpatients, Am J Psychiatry, vol.161, issue.1, pp.160-163, 2004. ,
Prevalence of neuroleptic-induced movement disorders: an 8-year follow-up study in chronic schizophrenia inpatients, Nord J Psychiatry, vol.70, issue.7, pp.498-502, 2016. ,
Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials, Schizophr Bull, vol.35, issue.2, pp.443-457, 2009. ,
Association of anticholinergic load with impairment of complex attention and memory in schizophrenia, Am J Psychiatry, vol.161, issue.1, pp.116-124, 2004. ,
Genetic Risk and Outcome of Psychosis (GROUP) Investigators. High Incidence and Prevalence of Drug-Related Movement Disorders in Young Patients With Psychotic Disorders, J Clin Psychopharmacol, vol.37, issue.2, pp.231-238, 2017. ,
Negative parkinsonian, depressive and catatonic symptoms in schizophrenia: a conflict of paradigms revisited, Schizophr Res, vol.40, issue.3, pp.245-253, 1999. ,
Parsing the components of the psychomotor syndrome in schizophrenia, Acta Psychiatr Scand, vol.126, issue.4, pp.256-265, 2012. ,
Psychomotor slowing, negative symptoms and dopamine receptor availability--an IBZM SPECT study in neuroleptic-treated and drug-free schizophrenic patients, Schizophr Res, vol.31, issue.1, pp.19-26, 1998. ,
MPP(+)-like neurotoxicity of a pyridinium metabolite derived from haloperidol: in vivo microdialysis and in vitro mitochondrial studies, J Pharmacol Exp Ther, vol.268, issue.1, pp.380-387, 1994. ,
Incidence of tardive dyskinesia in early stages of low-dose treatment with typical neuroleptics in older patients, Am J Psychiatry, vol.156, issue.2, pp.309-311, 1999. ,
Epidemiology of tardive dyskinesia: Is risk declining with modern antipsychotics?, Mov Disord, vol.21, issue.5, pp.589-598, 2006. ,
Schizophrenics with tardive dyskinesia. Neuropsychological deficit and family psychopathology, Arch Gen Psychiatry, vol.42, issue.9, pp.860-865, 1985. ,
An unusual cluster of tardive dyskinesia in schizophrenia: association with cognitive dysfunction and negative symptoms, Am J Psychiatry, vol.143, issue.9, pp.1162-1165, 1986. ,
Cognitive dysfunction, negative symptoms, and tardive dyskinesia in schizophrenia. Their association in relation to topography of involuntary movements and criterion of their abnormality, Arch Gen Psychiatry, vol.44, issue.10, pp.907-912, 1987. ,
Tardive dyskinesia in a chronically institutionalized population of elderly schizophrenic patients: prevalence and association with cognitive impairment, Int J Geriatr Psychiatry, vol.13, issue.7, pp.473-479, 1998. ,
Cognition impairment in schizophrenia patients with tardive dyskinesia: association with plasma superoxide dismutase activity, Schizophr Res, vol.152, issue.1, pp.210-216, 2014. ,
Altered BDNF is correlated to cognition impairment in schizophrenia patients with tardive dyskinesia, Psychopharmacology (Berl), vol.232, issue.1, pp.223-232, 2015. ,
Schizophrenia and dopamine receptors, Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol, vol.23, issue.9, pp.999-1009, 2013. ,
Markers of impaired motor and cognitive volition in Parkinson's disease: Correlates of dopamine dysregulation syndrome, impulse control disorder, and dyskinesias, Parkinsonism Relat Disord, 2017. ,